Literature DB >> 4581346

Creutzfeldt-Jakob disease treated with amantidine. A report of two cases.

W L Sanders, T L Dunn.   

Abstract

The treatment of two cases of Creutzfeldt-Jakob disease with amantidine is described. The first case made a remarkable initial improvement which was sustained for two months, but then deteriorated and died. Histological examination of the brain showed changes consistent with early Creutzfeldt-Jakob disease. The second case which was clinically one of Creutzfeldt-Jakob disease has now been followed for 30 months since the start of treatment and appears to be cured. It is considered that amantidine has a definite effect in this disease and it is suggested that its mode of action, though unknown, is more likely to be metabolic than antiviral.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4581346      PMCID: PMC494412          DOI: 10.1136/jnnp.36.4.581

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  On some aspects of cerebral degeneration in later life.

Authors:  S Nevin
Journal:  Proc R Soc Med       Date:  1967-06

2.  Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A 2 -Hong Kong infection. A controlled double-blind study.

Authors:  A W Galbraith; J S Oxford; G C Schild; C W Potter; G I Watson
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

3.  Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.

Authors:  J D Parkes; R C Baxter; G Curzon; R P Knill-Jones; P J Knott; C D Marsden; R Tattersall; D Vollum
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

Review 4.  Creutzfeldt-Jakob disease. 1. Survey of the literature and clinical diagnosis.

Authors:  W W May
Journal:  Acta Neurol Scand       Date:  1968       Impact factor: 3.209

5.  Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee.

Authors:  C J Gibbs; D C Gajdusek; D M Asher; M P Alpers; E Beck; P M Daniel; W B Matthews
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

6.  Jakob-Creutzfeldt disease: treatment by amantadine.

Authors:  J Braham
Journal:  Br Med J       Date:  1971-10-23
  6 in total
  9 in total

Review 1.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

2.  The ataxic (cerebellar) form of Creutzfeldt-Jakob disease.

Authors:  K Jellinger; W D Heiss; E Deisenhammer
Journal:  J Neurol       Date:  1974       Impact factor: 4.849

3.  Unusual clinical course in a case of Creutzfeldt-Jakob disease.

Authors:  G Villa; C Caltagirone; G Macchi
Journal:  Ital J Neurol Sci       Date:  1982-07

4.  Creutzfeld-Jakob disease: clinical, EEG and neuropathological findings in a cluster of eleven patients.

Authors:  A Lechi; F Tedeschi; D Mancia; V Pietrini; F Tagliavini; M G Terzano; G Trabattoni
Journal:  Ital J Neurol Sci       Date:  1983-04

5.  Use of aripiprazole in clozapine induced enuresis: report of two cases.

Authors:  Myung-Ji Lee; Chul-Eung Kim
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

6.  Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice.

Authors:  J Tateishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-08       Impact factor: 10.154

7.  The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection.

Authors:  R H Kimberlin; C A Walker
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

8.  Creutzfeldt-Jakob disease treated with amantadine.

Authors:  W L Sanders
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-10       Impact factor: 10.154

Review 9.  Prions and related neurological diseases.

Authors:  M Pocchiari
Journal:  Mol Aspects Med       Date:  1994
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.